Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine.
- Author(s): Ho, Dean
- Zarrinpar, Ali
- Chow, Edward Kai-Hua
- et al.
Published Web Locationhttps://doi.org/10.1021/acsnano.6b06174
The field of nanomedicine has already seen substantial progress in the clinic, with multiple formulations being evaluated through clinical studies. From poly(lactic-co-glycolic acid) and cyclodextrin-based drug-delivery platforms to metallic nanoparticles for photothermal treatment and imaging, nanotechnology has enabled versatile strategies to treat and to diagnose a wide range of disorders. However, as the field as a whole pushes forward, barriers that have always challenged conventional drug development have already started to impact nanomedicine translation. These include exorbitant costs, substantial time to development, and the uncertainty of achieving major improvements in efficacy or safety. Of note, there has been, until recent advances, a virtual inability to identify optimal drug doses either as monotherapies or components of combination therapy. In this Nano Focus, we assess how the impact of nanotechnology in the clinic can be optimized through systematically designed combinatorial nanotherapy. In addition, we provide a clinical perspective on how a recently unveiled technology platform can substantially alter the landscape of combinatorial nanomedicine, drug development, as well as conventional drug development.